IMGN News and Press, ImmunoGen Inc. From 01/29/20

5 Penny Stocks To Watch Before Friday This week we’ve seen a crazy mix of health concerns and economic uncertainty push the market all over the place. However, following the initial drop, the market has started to recover. Lack of volatility can make investors look for places where ther...

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 24,523,750 shares of its common stock at a price of $4.25 per share, which...

Genprex (NASDAQ: GNPX )  -37%  on pricing $8M stock offering. More news on: Genprex, Inc., Applied Genetic Technologies Corporation, Tetraphase Pharmaceuticals, Inc., Stocks on the move, , Read more ...

ImmunoGen (NASDAQ: IMGN ) has priced its public offering of 21,325,000 common shares at $4.25 per share, for expected gross proceeds of $90.6M. More news on: ImmunoGen, Inc., Healthcare stocks news, Stocks on the move, Read more ...

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 21,325,000 shares of its common stock at a price of $4.25 per share, before underwriting discoun...

The following healthcare companies have announced plans for public stock offerings: More news on: ImmunoGen, Inc., Misonix, Inc., Xenon Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more ...

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. ImmunoGe...

Introduction This forensic value analysis began with a check of four different algorithm scores of Tesla, Inc. (TSLA) at the request of members of my service back in October 2018. The question they asked at the time was, "what risk does Tesla, Inc. pose as an investment?" In an ad hoc query ...

ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 38 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The present...

ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 23, 2019 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purch...